ClinicalTrials.gg
CompletedNCT02925650DISCOVERUpdated May 9, 2023Results posted

Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease

A Phase 1/2 interventional study of Posiphen and Placebo in Alzheimer's Disease, sponsored by Annovis Bio Inc.. Completed at 6 sites in United States. Open to participants aged 55 Years to 89 Years. Per ClinicalTrials.gov, last updated 2023-05-09.

Sponsored by Annovis Bio Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
55 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
1,330th of 1,609
18 · median 73
Started
2017
with 68 others
Phase 1/2
67 of 1,940
17 open now
Registered
818th of 1,940
by date

Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 1,330th largest by enrollment of the 1,609 interventional ones that give a count, is one of 69 that started in 2017, is one of 67 in phase 1/2, and was the 818th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 89 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,940 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

This study evaluates the safety and pharmacological effects of 3 different doses of Posiphen® when compared to a placebo, in adult male and female patients with early Alzheimer's disease (AD).

Read the detailed description

Posiphen®, which was discovered by the US National Institute on Aging (NIA) is a small, orally active, experimental drug that specifically inhibits the synthesis of amyloid precursor protein (APP), Tau and α-Synuclein. It is distinct from other Alzheimer's disease drugs currently in development, because it inhibits the formation of several toxic proteins, rather than removing individual toxic protein after they are produced. Posiphen has potential utility as a disease modifying treatment for AD. The present study will confirm the pharmacokinetics (PK) of Posiphen and its metabolites in plasma and cerebral spinal fluid (CSF). It will also measure the effects of a 23-25 day treatment period with Posiphen on the CSF and plasma levels of a number of biomarkers, inflammatory factors and control proteins. It will also expand the safety data in humans by extending the treatment period from 10 days to a treatment period from 23-25 days. In addition, this study will measure concentrations of various soluble biomarkers in CSF and use the SILK™ assay methods to directly measure the effect of Posiphen on the fractional synthesis rate of Aβ40 in CSF, which will help guide the further development of Posiphen and determine the feasibility of SILK™ in a multicenter trial.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

Keywords

  • Alzheimer's Disease
  • SILK™
  • Pharmacodynamics
  • Safety
  • Pharmacokinetics
04

Who can participate

Ages eligible
55 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged 55 to 89 years (inclusive), in good health, no frailty.
  2. Female participants must be for at least 2 consecutive years or surgically sterile (bilateral tubal ligation, hysterectomy or bilateral oophorectomy) for at least 6 months prior to screening.
  3. Female participants will be given a urine pregnancy test at the screening visit for which they should test negative.
  4. Clinical profile consistent with MCI or mild AD, consistent with the core clinical criteria outlined in the NIA-AA Guidelines (2011).
  5. score between 17 and 30 (inclusive).
  6. CDR global score of 0.5 with a memory score of 0.5 or greater, or CDR global score of 1.0.
  7. Participant likely to tolerate all study procedures per PI judgment.
  8. To qualify for entry, subjects will have a CSF Abeta42-Abeta40 ratio below 0.131 that is consistent with Alzheimers disease as measured via mass spectrometry by C2N.
  9. General cognition and functional performance sufficiently preserved that the subject can provide written .
  10. A minimum of 6 years of education or good work history.
  11. Study partner is available who has frequent contact with the subject (e.g., average of 10 hours per week or more), and can accompany the subject to most visits to answer questions about the subject. The study partner is required to attend the entire screening visit and the baseline visit. The study drug is dispensed to the participant at the baseline visit and the study partner (or other individual) should also oversee study drug administration if needed to ensure compliance with dose regimen. At a minimum, the study partner should stay for the first 3 hours of the confinement visit and return at the discharge to drive the subject home.
  12. No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the Columbia Suicide Severity Rating Scale.
  13. MRI scan within the 12 months prior to screening without evidence of infection, infarction, or other focal lesions and without clinical symptoms suggestive of intervening neurological disease. Lacunes that are not believed to contribute to the subjects cognitive impairment are permissible. If there is no MRI available within a 12-month timeframe, then an MRI must be performed as part of the screening procedures for eligibility.
  14. Stability of permitted medications for 4 weeks prior to baseline. NOTE: Cholinesterase inhibitors and or memantine are allowable only if stable for 12 weeks prior to screen. If taking Arciept (donezepil), no more than 10 mg/day is permitted during the course of the study.
  15. Adequate visual and hearing ability (physical ability to perform all the study assessments).
  16. Good general health with no disease expected to interfere with the study. Subjects may have common age-related disorders (i.e., hypertension, type II diabetes, dyslipidemia, and hypothyroidism) as long as these disorders are being controlled by diet or medication.
  17. Must speak English, Spanish, or Korean fluently.

Exclusion criteria

Exclusion Criteria:

  1. Has a history of a psychiatric disorder such as schizophrenia, bipolar disorder or major depression according to the criteria of the most current version of the (DSM). Mild depression or history of depression that is stable on treatment with a tricyclic antidepressant SSRI or SNRI medication at a stable dose is acceptable.
  2. Other neurodegenerative diseases, including Parkinsons disease and Huntingtons disease, or cerebral tumor.
  3. Dementia other than AD, such as Acquired Immunodeficiency Syndrome (AIDS), Creutzfeldt-Jakob disease (CJD), Lewy Bodies dementia (LBD), Cerebrovascular dementia (CVD), Progressive Supranuclear Palsy (PSP), or normal pressure hydrocephalus (NPH).
  4. History of a seizure disorder.
  5. abnormalities in screening laboratory or results.
  6. Has current serious or unstable illness including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease or other conditions that, in the investigators opinion, makes them ineligible for participation in this study.
  7. Has four or more microinfarcts as noted in the MRI scan.
  8. Has cancer or has had a malignant tumor within the past 3 years, except patients who underwent potentially curative therapy with no evidence of recurrence. (Patients with stable untreated prostate cancer or skin cancers are not excluded).
  9. According to the criteria of the most current version of the DSM, alcohol abuse, alcohol dependence, or drug abuse in the past 5 years.
  10. Participation in another clinical trial with an agent and have taken at least one dose of study medication, unless unblinded on placebo, within 16 weeks prior to screening. (The end of a previous investigational trial is the date the last dose of an investigational agent was taken).
  11. Resides in a skilled nursing facility.
  12. Subjects with infection or inflammation of the skin or skin disease at or in proximity to the lumbar puncture site.
  13. History of lumbar spine surgery or chronic low back pain (CLBP).
  14. Subjects whom the site PI deems to be otherwise ineligible.
  15. Has a deep brain stimulator (DBS).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Low Dose

    The study drug Posiphen dosage of 60mg is to be taken orally in divided doses, three times per day for a total 23-25 days.

    Drug: Posiphen

  • Experimental
    Medium Dose

    The study drug Posiphen dosage of 120mg is to be taken orally in divided doses, three times per day for a total 23-25 days.

    Drug: Posiphen

  • Experimental
    High Dose

    The study drug Posiphen dosage of 180mg is to be taken orally in divided doses, three times per day for a total 23-25 days.

    Drug: Posiphen

  • Placebo comparator
    Placebo

    The Placebo comparator is to be taken orally in divided doses, three times per day for a total 23-25 days.

    Drug: Placebo

Interventions

  • oral solid dosage form capsule

  • DrugPlacebo

    oral solid dosage form capsule

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability of Multiple Ascending Doses of Posiphen: Reports of Adverse Events or Study Discontinuations

    Number of adverse events or study discontinuations, broken down by dose arm (i.e. Low vs. Medium vs. High vs. Placebo), and further broken down by relatedness to Posiphen (Definitely Related, Probably Related, Possibly Related, Unlikely Related, Unrelated)

    Time frame: Up to 25 days

  2. The Levels of Posiphen and Its Metabolites Will be Determined in Plasma

    Mean plasma concentrations of levels of posiphen tartrate, N1 desmethyl posiphen, and N8 desmethyl Posiphen metabolite were determined for each of the three dose cohorts (Low Dose, Medium Dose, High Dose) by a protein precipitation extraction method using a high performance liquid chromatographic mass spectrometric detection method, with a linear weighted regression to determine their concentrations.

    Time frame: The confinement visit occurred following 21-23 days of treatment with either Posiphen or placebo, while also allowing a +/- 2-day visit window. Plasma was collected at 0, 2, 4, 8, 12, 16, 20, and 24hrs during the confinement visit.

  3. The Levels of Posiphen and Its Metabolites Will be Determined in Cerebrospinal Fluid (CSF)

    Mean CSF concentrations of levels of posiphen tartrate, N1 desmethyl posiphen, and N8 desmethyl Posiphen metabolite were determined for each of the three dose cohorts (Low Dose, Medium Dose, High Dose) by a protein precipitation extraction method using a high performance liquid chromatographic mass spectrometric detection method, with a linear weighted regression to determine the concentrations.

    Time frame: The confinement visit occurred following 21-23 days of treatment with either Posiphen or placebo, while also allowing a +/- 2-day visit window. Plasma was collected at 0, 2, 4, 8, 12, 16, 20, and 24hrs during the confinement visit.

  4. Fractional Synthesis Rate of Aβ40 in CSF Using the SILK™ Technique With Multiple Doses of Posiphen

    The fractional synthesis rate (FSR) of Aβ40 was measured in the CSF using the SILK™ technique. FSR is a measure of the rate of Aβ synthesis in the brain. During 13C6-leucine infusion, 13C6-leucine is incorporated into newly synthesized proteins throughout the body, including the brain, in proportion to the available 13C6-leucine. This FSR is calculated as the rate of change of the ratio of 13C6-leucine-labeled Aβ proteins to unlabeled Aβ proteins in the lumbar CSF between 6 to 16 hours, normalized to the ratio of labeled to unlabeled leucine amino acid in plasma. It is reported as a fraction of 13C6-leucine-labeled to unlabeled Aβ proteins per hour. The ratio of Aβ in CSF containing 13C6-leucine to that containing unlabeled leucine is measured using mass spectrometry.

    Time frame: The confinement visit occurred following 21-23 days of treatment with either Posiphen or placebo, while also allowing a +/- 2-day visit window. CSF was collected between 6 and 16hrs during the confinement visit.

Secondary outcomes

  1. Feasibility of CSF Catheter Study With SILK™ Technology to Evaluate Rates of Enrollment

    Feasibility of CSF Catheter Study with SILK™ Technology was determined by comparing the total number of participants enrolled, randomized and treated with study drug in the trial to the total number of participants who completed the CSF Catheter Study across all participating sites.

    Time frame: Up to 25 days

  2. Feasibility of CSF Catheter Study With SILK™ Technology to Evaluate %CSF Samples With Enough Volume for Testing

    The % of cerebrospinal fluid samples with sufficient volume for testing will be determined across study participants during the SILK sampling procedure

    Time frame: Up to 25 days

  3. Feasibility of CSF Catheter Study With SILK™ Technology to Evaluate Research Satisfaction

    Research satisfaction will be evaluated by qualitative response to 14 questions asked to participants about their experience with the study procedures. Responses will be grouped and reported by common themes

    Time frame: Up to 25 days

  4. Pharmacodynamic and PK-PD Effects on CSF Alzheimer's Disease Biomarkers

    Aβ38, Aβ40, Aβ42, sAPPα, sAPPβ, and T-Tau were sampled at Screening and at the start of the confinement visit. Results of these measures were reported as a least square means, calculated as the change between the measured values at the start of the confinement visit and Screening in ng/mL.

    Time frame: CSF was sampled at Screening and at the start of the confinement visit, which occurred following 21-23 days of treatment with either Posiphen or placebo, while also allowing a +/- 2-day visit window.

  5. Assessment of Mental Status Effects

    The short-term effects of Posiphen on mental status will be measured using the Mini-Mental State Examination (MMSE). The MMSE is a brief, global cognitive measure that includes orientation, memory, attention, concentration, naming, writing, repetition, comprehension, and construction. The total score ranges from 0 (worst) to 30 (best performance). Results of the MMSE for this trial were reported as a raw change score, calculated as the change between the total scores at two evaluation time points (Baseline, Pre-Confinement Visit) and where negative values are worse and positive values are better.

    Time frame: MMSE was administered at Baseline and at the Pre-Confinement Visit 1-3 days prior to the Confinement Visit. This confinement visit occurred following 21-23 days of treatment with either Posiphen or placebo, while also allowing a +/- 2-day visit window.

  6. Assessment of Neuropsychiatric Effects

    The Neuropsychiatric Inventory (NPI) was used to measure the frequency and severity of neuropsychiatric symptoms. On this scale frequency ratings range from 0 (no symptoms) to 4 (very frequently, once or more per day or continuously). Severity ratings range from 0 (no severity) to 3 (severe). The score for each of 12 symptoms measured in the scale is the product of severity and frequency within that symptom. The total score for the NPI is the sum of all 12 symptom item scores, for a highest possible total score of 144 in individuals with maximal symptoms, and a lowest possible total score of zero (0) in fully asymptomatic individuals. Lower scores are better and higher scores indicate more neuropsychiatric symptoms. Results are calculated as the change between the total scores at two evaluation time points (Baseline, Pre-Confinement Visit) with negative scores being better and positive scores being worse.

    Time frame: NPI was administered at Baseline and at the Pre-Confinement Visit 1-3 days prior to the Confinement Visit. This confinement visit occurred following 21-23 days of treatment with either Posiphen or placebo, while also allowing a +/- 2-day visit window.

  7. Assessment of Cognitive Effects

    The short-term effects of Posiphen on cognition were measured using the The Alzheimer's Disease Assessment Scale-Cognitive 12 (ADAS-Cog12). The ADAS-Cog is a structured scale that evaluates memory (word recall, word recognition), reasoning, language (naming, comprehension), orientation, ideational praxis and constructional praxis. The test is scored in terms of errors, with higher scores reflecting poorer performance and greater impairment. Total ADAS-Cog12 scores can range from 0 to 80, with lower scores being better and higher scores being worse. Results of the ADAS-Cog12 for this trial are reported as a raw change score, calculated as the change between the total scores at two evaluation time points (Baseline, Pre-Confinement Visit) with negative scores being better and positive scores being worse.

    Time frame: ADAS-Cog12 was administered at Baseline and at the Pre-Confinement Visit 1-3 days prior to the Confinement Visit. This confinement visit occurred following 21-23 days of treatment with either Posiphen or placebo, also allowing a +/- 2-day visit window.

07

Results

Posted May 9, 2023

Participant flow

Participant flow — Overall Study
MilestoneLow DoseMedium DoseHigh DosePlacebo
Started5517
Completed4515
Not completed1002

Outcome measures

PrimarySafety and Tolerability of Multiple Ascending Doses of Posiphen: Reports of Adverse Events or Study Discontinuations

Number of adverse events or study discontinuations, broken down by dose arm (i.e. Low vs. Medium vs. High vs. Placebo), and further broken down by relatedness to Posiphen (Definitely Related, Probably Related, Possibly Related, Unlikely Related, Unrelated)

Time frame:
Up to 25 days
Reported as:
Number · events
Safety and Tolerability of Multiple Ascending Doses of Posiphen: Reports of Adverse Events or Study Discontinuations
eventsLow DoseMedium DoseHigh DosePlacebo
Definitely Related0000
Probably Related0100
Possibly Related1002
Unlikely Related2302
Unrelated91106
Total1215010
PrimaryThe Levels of Posiphen and Its Metabolites Will be Determined in Plasma

Mean plasma concentrations of levels of posiphen tartrate, N1 desmethyl posiphen, and N8 desmethyl Posiphen metabolite were determined for each of the three dose cohorts (Low Dose, Medium Dose, High Dose) by a protein precipitation extraction method using a high performance liquid chromatographic mass spectrometric detection method, with a linear weighted regression to determine their concentrations.

Time frame:
The confinement visit occurred following 21-23 days of treatment with either Posiphen or placebo, while also allowing a +/- 2-day visit window. Plasma was collected at 0, 2, 4, 8, 12, 16, 20, and 24hrs during the confinement visit.
Reported as:
Mean · ng/mL
The Levels of Posiphen and Its Metabolites Will be Determined in Plasma
ng/mLLow DoseMedium DoseHigh Dose
Posiphen7.16 ± 4.259.51 ± 5.7712.01 ± 0
N1 metabolite1.29 ± 0.773.02 ± 1.42.51 ± 0
N8 metabolite2.25 ± 1.365.04 ± 1.83.35 ± 0
PrimaryThe Levels of Posiphen and Its Metabolites Will be Determined in Cerebrospinal Fluid (CSF)

Mean CSF concentrations of levels of posiphen tartrate, N1 desmethyl posiphen, and N8 desmethyl Posiphen metabolite were determined for each of the three dose cohorts (Low Dose, Medium Dose, High Dose) by a protein precipitation extraction method using a high performance liquid chromatographic mass spectrometric detection method, with a linear weighted regression to determine the concentrations.

Time frame:
The confinement visit occurred following 21-23 days of treatment with either Posiphen or placebo, while also allowing a +/- 2-day visit window. Plasma was collected at 0, 2, 4, 8, 12, 16, 20, and 24hrs during the confinement visit.
Reported as:
Mean · ng/mL
The Levels of Posiphen and Its Metabolites Will be Determined in Cerebrospinal Fluid (CSF)
ng/mLLow DoseMedium DoseHigh Dose
Posiphen0.46 ± 0.30.73 ± 0.520.71 ± 0
N1 metabolite0.02 ± 0.040.28 ± 0.30 ± 0
N8 metabolite0.35 ± 0.260.77 ± 0.430.15 ± 0
PrimaryFractional Synthesis Rate of Aβ40 in CSF Using the SILK™ Technique With Multiple Doses of Posiphen

The fractional synthesis rate (FSR) of Aβ40 was measured in the CSF using the SILK™ technique. FSR is a measure of the rate of Aβ synthesis in the brain. During 13C6-leucine infusion, 13C6-leucine is incorporated into newly synthesized proteins throughout the body, including the brain, in proportion to the available 13C6-leucine. This FSR is calculated as the rate of change of the ratio of 13C6-leucine-labeled Aβ proteins to unlabeled Aβ proteins in the lumbar CSF between 6 to 16 hours, normalized to the ratio of labeled to unlabeled leucine amino acid in plasma. It is reported as a fraction of 13C6-leucine-labeled to unlabeled Aβ proteins per hour. The ratio of Aβ in CSF containing 13C6-leucine to that containing unlabeled leucine is measured using mass spectrometry.

Time frame:
The confinement visit occurred following 21-23 days of treatment with either Posiphen or placebo, while also allowing a +/- 2-day visit window. CSF was collected between 6 and 16hrs during the confinement visit.
Reported as:
Mean · fraction labeled:unlabeled Aβ40 per hr
Fractional Synthesis Rate of Aβ40 in CSF Using the SILK™ Technique With Multiple Doses of Posiphen
fraction labeled:unlabeled Aβ40 per hrLow DoseMedium DoseHigh DosePlacebo
Fractional Synthesis Rate of Aβ40 in CSF Using the SILK™ Technique With Multiple Doses of Posiphen0.0405 (0.0298 to 0.0431)0.0400 (0.0373 to 0.0511)0.0206 (0.0206 to 0.0206)0.0375 (0.0319 to 0.0449)
SecondaryFeasibility of CSF Catheter Study With SILK™ Technology to Evaluate Rates of Enrollment

Feasibility of CSF Catheter Study with SILK™ Technology was determined by comparing the total number of participants enrolled, randomized and treated with study drug in the trial to the total number of participants who completed the CSF Catheter Study across all participating sites.

Time frame:
Up to 25 days
Reported as:
Count of participants · Participants
Feasibility of CSF Catheter Study With SILK™ Technology to Evaluate Rates of Enrollment
ParticipantsActive Treatment ArmsPlacebo Arm
Feasibility of CSF Catheter Study With SILK™ Technology to Evaluate Rates of Enrollment105
SecondaryFeasibility of CSF Catheter Study With SILK™ Technology to Evaluate %CSF Samples With Enough Volume for Testing

The % of cerebrospinal fluid samples with sufficient volume for testing will be determined across study participants during the SILK sampling procedure

Time frame:
Up to 25 days
Reported as:
Number · percentage of CSF samples
Feasibility of CSF Catheter Study With SILK™ Technology to Evaluate %CSF Samples With Enough Volume for Testing
percentage of CSF samplesAll Randomized Participants Who Completed 36 Hour Confinement Visit (n=15)
Feasibility of CSF Catheter Study With SILK™ Technology to Evaluate %CSF Samples With Enough Volume for Testing81.75
SecondaryFeasibility of CSF Catheter Study With SILK™ Technology to Evaluate Research Satisfaction

Research satisfaction will be evaluated by qualitative response to 14 questions asked to participants about their experience with the study procedures. Responses will be grouped and reported by common themes

Time frame:
Up to 25 days
Reported as:
Number · percentage of participants
Feasibility of CSF Catheter Study With SILK™ Technology to Evaluate Research Satisfaction
percentage of participantsAll Randomized Participants
Rated "Excellent" for quality of tests and attention received during participation in the study.94
Reported "Almost all of my expectations have been met" by the research program.81
Reported "Yes, definitely" they would recommend this research program to a friend.94
Reported "Yes, definitely" they would choose to participate again.87.5
Reported "Volunteering" as what they liked best about the study.31
Reported "Time Commitment" as what they liked least about the study.31
Reported "Yes", the 36 hour catheter procedure was done.100
Reported "No" adverse events were associated with the 36hr catheter procedure.73
Reported "Excellent" as the quality of the 36hr catheter procedure and attention they received.80
Reported the catheter procedure was "almost all of what I expected."67
Reported they liked best was "participating in cutting edge research and interacting with the team".100
Reported "Other" as what they liked least about the 36hr catheter procedure.47
Reported "Other" as what they would change about the 36hr catheter procedure.71
Reported they would change the number of visits.50
SecondaryPharmacodynamic and PK-PD Effects on CSF Alzheimer's Disease Biomarkers

Aβ38, Aβ40, Aβ42, sAPPα, sAPPβ, and T-Tau were sampled at Screening and at the start of the confinement visit. Results of these measures were reported as a least square means, calculated as the change between the measured values at the start of the confinement visit and Screening in ng/mL.

Time frame:
CSF was sampled at Screening and at the start of the confinement visit, which occurred following 21-23 days of treatment with either Posiphen or placebo, while also allowing a +/- 2-day visit window.
Reported as:
Least squares mean · ng/mL
Pharmacodynamic and PK-PD Effects on CSF Alzheimer's Disease Biomarkers
ng/mLActive Treatment ArmsPlacebo Arm
Aβ380.391 ± 0.1730.593 ± 0.199
Aβ401.73 ± 0.9983.13 ± 1.151
Aβ420.107 ± 0.06530.211 ± 0.0753
sAPPα6.49 ± 5.75-3.5 ± 9.07
sAPPβ19.1 ± 16.8-28.6 ± 26.5
Total Tau186.4 ± 79.153.7 ± 124.9
SecondaryAssessment of Mental Status Effects

The short-term effects of Posiphen on mental status will be measured using the Mini-Mental State Examination (MMSE). The MMSE is a brief, global cognitive measure that includes orientation, memory, attention, concentration, naming, writing, repetition, comprehension, and construction. The total score ranges from 0 (worst) to 30 (best performance). Results of the MMSE for this trial were reported as a raw change score, calculated as the change between the total scores at two evaluation time points (Baseline, Pre-Confinement Visit) and where negative values are worse and positive values are better.

Time frame:
MMSE was administered at Baseline and at the Pre-Confinement Visit 1-3 days prior to the Confinement Visit. This confinement visit occurred following 21-23 days of treatment with either Posiphen or placebo, while also allowing a +/- 2-day visit window.
Reported as:
Mean · score on a scale
Assessment of Mental Status Effects
score on a scaleLow DoseMedium DoseHigh DosePlacebo
Assessment of Mental Status Effects-1.4 ± 0.891.2 ± 2.39-1 ± 01.14 ± 2.12
SecondaryAssessment of Neuropsychiatric Effects

The Neuropsychiatric Inventory (NPI) was used to measure the frequency and severity of neuropsychiatric symptoms. On this scale frequency ratings range from 0 (no symptoms) to 4 (very frequently, once or more per day or continuously). Severity ratings range from 0 (no severity) to 3 (severe). The score for each of 12 symptoms measured in the scale is the product of severity and frequency within that symptom. The total score for the NPI is the sum of all 12 symptom item scores, for a highest possible total score of 144 in individuals with maximal symptoms, and a lowest possible total score of zero (0) in fully asymptomatic individuals. Lower scores are better and higher scores indicate more neuropsychiatric symptoms. Results are calculated as the change between the total scores at two evaluation time points (Baseline, Pre-Confinement Visit) with negative scores being better and positive scores being worse.

Time frame:
NPI was administered at Baseline and at the Pre-Confinement Visit 1-3 days prior to the Confinement Visit. This confinement visit occurred following 21-23 days of treatment with either Posiphen or placebo, while also allowing a +/- 2-day visit window.
Reported as:
Mean · score on a scale
Assessment of Neuropsychiatric Effects
score on a scaleLow DoseMedium DoseHigh DosePlacebo
Assessment of Neuropsychiatric Effects-2.6 ± 2.883.4 ± 8.47-9 ± 0-3.86 ± 8.09
SecondaryAssessment of Cognitive Effects

The short-term effects of Posiphen on cognition were measured using the The Alzheimer's Disease Assessment Scale-Cognitive 12 (ADAS-Cog12). The ADAS-Cog is a structured scale that evaluates memory (word recall, word recognition), reasoning, language (naming, comprehension), orientation, ideational praxis and constructional praxis. The test is scored in terms of errors, with higher scores reflecting poorer performance and greater impairment. Total ADAS-Cog12 scores can range from 0 to 80, with lower scores being better and higher scores being worse. Results of the ADAS-Cog12 for this trial are reported as a raw change score, calculated as the change between the total scores at two evaluation time points (Baseline, Pre-Confinement Visit) with negative scores being better and positive scores being worse.

Time frame:
ADAS-Cog12 was administered at Baseline and at the Pre-Confinement Visit 1-3 days prior to the Confinement Visit. This confinement visit occurred following 21-23 days of treatment with either Posiphen or placebo, also allowing a +/- 2-day visit window.
Reported as:
Mean · score on a scale
Assessment of Cognitive Effects
score on a scaleActive Treatment ArmsPlacebo Arm
Assessment of Cognitive Effects-0.55 ± 6.04-1.57 ± 5.19

Adverse events

Collected over From Randomization through Study Day 25.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Low Dose0/5 (0%)0/5 (0%)5/5 (100%)
Medium Dose0/5 (0%)0/5 (0%)4/5 (80%)
High Dose0/1 (0%)0/1 (0%)0/1 (0%)
Placebo0/7 (0%)0/7 (0%)4/7 (57.1%)
Most frequent other events
Showing 10 of 27
Most frequent other events
EventLow DoseMedium DoseHigh DosePlacebo
headacheNervous system disorders1/52/50/13/7
medical device complicationGastrointestinal disorders0/52/50/10/7
pain in extremityMusculoskeletal and connective tissue disorders2/50/50/10/7
post lumbar puncture syndromeInjury, poisoning and procedural complications2/51/50/11/7
tremorNervous system disorders0/50/50/12/7
agitationPsychiatric disorders0/51/50/10/7
back painMusculoskeletal and connective tissue disorders1/50/50/10/7
coughRespiratory, thoracic and mediastinal disorders0/51/50/10/7
diarrhoeaGastrointestinal disorders0/51/50/10/7
fatigueGeneral disorders1/50/50/10/7

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Low DoseMedium DoseHigh DosePlaceboTotal
<=18 years00000
Between 18 and 65 years12115
>=65 years430613
Sex: Female, Male
Sex: Female, Male(Participants)Low DoseMedium DoseHigh DosePlaceboTotal
Female50038
Male051410
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Low DoseMedium DoseHigh DosePlaceboTotal
White551617
Unknown, Not Reported00011
Not-Hispanic or Latino551617
Hispanic or Latino00011
Region of Enrollment
Region of Enrollment(participants)Low DoseMedium DoseHigh DosePlaceboTotal
United States551718
08

Study locations

6 sites
  • UCSD Alzheimer's Disease Research Center
    La Jolla, California 92037, United States
  • IU Health Partners, Adult Neurology Clinic
    Indianapolis, Indiana 46202, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Washington University Sleep Medicine Center
    Brentwood, Missouri 63144, United States
  • Columbia University Medical Center Sergievsky Center Taub Institute
    New York, New York 10032, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this research will be shared with other researchers pursuant to the 02/26/2003 "NIH Final Statement on Sharing Research Data". The ADCS through its Data and Sample Sharing Committee (DSSC) will receive requests for sample and data sharing. The ADCS grants access to de-identified data to qualified scientists who complete the request process and agree to conditions in an ADCS/UCSD Data Use Agreement (DUA) and the ADCS Publications Policy. After approval and receipt of the fully executed DUA, applicants are authorized to acquire data. Non-compliance with the DUA, including the requirement to provide requested updates will jeopardize further access to data. The same process and Committee reviews and approves biosample requests. If a request for biosample sharing is approved, a Material Transfer Agreement (MTA) will be negotiated between UCSD/ADCS and the requesting researcher or organization.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: 01 August 2023

Access criteria: Data requestors must complete an ADCS Data and Sample Sharing request form which will be reviewed by the ADCS DSSC. Upon approval, requestors must complete a Data Use Agreement (DUA) prior to accessing the data.

Data sharing details ↗ · www.adcs.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Dec 2021, 57 months.

Results were first posted in May 2023, 1 year 4 months after primary completion.

Of 62 phase 1/2 interventional studies under Alzheimer Disease, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 63. This study's 57 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2016
First posted
Oct 6, 2016
StartActual
Mar 2, 2017
Primary completionActual
Dec 10, 2021
CompletionActual
Dec 31, 2021
Results first posted
May 9, 2023
Last update
May 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02925650
Lead sponsor
Annovis Bio Inc.
Collaborators
Alzheimer's Disease Cooperative Study (ADCS)
Responsible party
Sponsor
First posted
Oct 6, 2016
Start date
Mar 2, 2017
Primary completion
Dec 10, 2021
Completion
Dec 31, 2021
Results posted
May 9, 2023
Last update
May 9, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Buntanetap

Start the discussion